When was Siwei Biotechnology founded?

Siwei Biotechnology was founded in 2016.

Where is Siwei Biotechnology located?

Siwei Biotechnology is headquartered in Pudong, China.

Is Siwei Biotechnology a funded company?

Siwei Biotechnology is a funded company, having raised a total of $206M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of Siwei Biotechnology?

Siwei Biotechnology's latest funding was a $***** Series C round on Jun 03, 2021, with participation from 7 investors. Its primary sector is Drug Delivery. In China, the Drug Delivery sector has seen $118M in funding in 2026 to date.

Where does Siwei Biotechnology rank among its competitors?

Siwei Biotechnology ranks 91st amongst 312 active competitors, of which 91 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was OliX Pharmaceuticals, which secured $72.7M in Jun, 2026.

Who are the top competitors of Siwei Biotechnology?

Siwei Biotechnology's top competitors include Liquidia, Orna and Genedit. Among them, OliX Pharmaceuticals secured the most recent funding round in June, 2026.

Siwei Biotechnology - 2026 Company Profile, Team, Funding & Competitors

Siwei Biotechnology is a deadpooled company based in Pudong (China), founded in 2016 by Li Hangwen. It operates as a Developer of nanocarrier delivery platform for mRNA vaccines. Siwei Biotechnology has raised $206M in funding from investors like Sequoia Capital, WuXi AppTec and Greenwoods Investments. The company has 312 active competitors, including 91 funded and 39 that have exited. Its top competitors include companies like Liquidia, Orna and Genedit.

Company Details

Developer of nanocarrier delivery platform for mRNA vaccines. The LPP/mRNA is a patented nano model for delivering mRNA drugs through two-layer structure technology. The company has developed mRNA-based personalized therapeutics which are delivered through the delivery platform for treating cancer, infectious disease, protein defects diseases, and genetic diseases.

Website: stemirna.com
Email ID: *****@stemirna.com
Phone Number: +86 **********

Key Metrics

Founded Year

2016

Location

Pudong, China

Stage

Deadpooled

Total Funding

$206M in 4 rounds

Latest Funding Round

Series C, Jun 03, 2021, $*****

Investors

Sequoia Capital & 12 more

Ranked

91^st among 312 active competitors

Similar Companies

Liquidia & 405 more

View Siwei Biotechnology's full profile

Siwei Biotechnology has raised a total funding of $206M over 4 rounds. Its latest funding round was a Series C round on Jun 03, 2021 for $*****. 7 investors participated in its latest round. Siwei Biotechnology has 13 institutional investors.

Here is the list of recent funding rounds of Siwei Biotechnology:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 03, 2021	4386998	Series C	7819265	9379708	3991949	8367419
Feb 05, 2020	7147064	Series A	8764666	9544886	9201115	Junshi BioPharma
Aug 12, 2019	1531871	Series A	1897782	9667660	Longmen Capital & 1 more	9358443

Access funding benchmarks and valuations. Sign up today!

View details of Siwei Biotechnology's funding rounds and investors

The founders of Siwei Biotechnology is Li Hangwen.

Here are the details of Siwei Biotechnology's key team members:

Li Hangwen: Founder of Siwei Biotechnology.
Contact Info: 1 email address

View details of Siwei Biotechnology's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Siwei Biotechnology include Liquidia, Orna and Genedit. Here is the list of Top 10 competitors of Siwei Biotechnology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Liquidia 2004, Morrisville (United States), Public	Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions	$90.3M	Morningside, Canaan & 18 others	68/100
2nd	Orna 2020, Cambridge (United States), Acquired	Developer of technologies for producing circular RNA therapeutics	$201M	F2 Ventures, Taiho Ventures & 7 others	67/100
3rd	Genedit 2016, Berkeley (United States), Series B	Developer of drug delivery system for genetic medicines	$93.5M	IMM Investment, SK & 20 others	65/100
4th	Rznomics 2017, Yongin si (South Korea), Public	Developer of drugs for anti-cancer and refractory diseases based on RNA Platform technology	$48.7M	QUAD, Korea Development Bank Europe & 13 others	62/100
5th	Aera 2021, Boston (United States), Series B	Developer of genetic medicines across a wide range of therapeutic areas	$193M	Arch Venture Partners, Google Ventures & 3 others	62/100
6th	NanoSyrinx 2018, Coventry (United Kingdom), Series A	Developer of targeted intracellular delivery platform for biological molecules	$21.6M	Octopus Ventures, M Ventures & 15 others	61/100
7th	OliX Pharmaceuticals 2010, Suwon-si (South Korea), Public	Developer of RNAi therapeutics for dermal, ophthalmic and pulmonary diseases.	-	IMM Investment, Weiss Asset Management & 16 others	61/100
8th	Dicerna Pharmaceuticals 2007, Lexington (United States), Acquired	Developer of drugs by using RNA interference technology platform	$106M	RA Capital Management, Domain Associates ... & 18 others	60/100
9th	Helex 2021, New York City (United States), Seed	Provider of next-generation gene-editing therapies	$6M	pi Ventures, IndieBio & 2 others	59/100
10th	Vaxxas 2010, Brisbane (Australia), Series D	Developer of a needle-free patch technology for vaccine delivery applications	$91.2M	One Ventures, UniQuest & 12 others	58/100
91st	Siwei Biotechnology 2016, Pudong (China), Deadpooled	Developer of nanocarrier delivery platform for mRNA vaccines	$206M	Spinnotec, Orbimed & 11 others	34/100